Switch maintenance therapy for advanced stomach or esophageal cancer
Treatments studied
This trial tests a combination of three drugs (paclitaxel, ramucirumab, and tislelizumab) as a maintenance therapy after initial chemotherapy for advanced stomach or esophageal cancer. It aims to see if this switch helps keep the cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced stomach or esophageal cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer is HER2-negative (a type of cancer) and has a PD-L1 TAP score of at least 5% (a protein level).
- You have not had any prior treatment for metastatic disease, but you may have had earlier therapy if the cancer returned more than 6 months after finishing it.
- Your cancer can be measured or evaluated by scans.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- You have adequate organ function (kidney, liver, bone marrow, etc.) as shown by lab tests.
- You are willing to use effective contraception during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests combining chemotherapy (FOLFOX) with an immunotherapy drug (Toripalimab) before and after surgery for a type of stomach cancer called HER2-negative adenocarcinoma of the esophagogastric junction. It may help shrink the tumor and improve outcomes.
This trial tests whether combining different drugs before and after surgery can help people with locally advanced stomach cancer that can't be removed right away. The goal is to see which combination works best to shrink the tumor and improve outcomes.
This Phase 1 study tests CA-4948 given with standard chemotherapy (FOLFOX) and an immune therapy (an immune checkpoint inhibitor, similar to PD-1). It’s for people with advanced stomach or esophageal cancer that can’t be removed by surgery, to see how well the treatment works and whether it’s safe.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.